Literature DB >> 16253350

An emerging role for PtdIns(4,5)P2-mediated signalling in human disease.

Jonathan R Halstead1, Kees Jalink, Nullin Divecha.   

Abstract

Although an established regulator of many cellular functions, the phosphoinositide phosphatidylinositol (4,5)-bisphosphate [PtdIns(4,5)P2) appears to have evaded the attention of drug-discovery companies. An increasing number of reports have identified potential links between PtdIns(4,5)P2-mediated signalling pathways and the aetiology of many human diseases. Here, we review current knowledge of the regulation and function of PtdIns(4,5)P2 and discuss how aberrant PtdIns(4,5)P2-mediated signalling might contribute to human pathologies such as cardiac failure, bipolar disorder, channelopathies and the genetic disorder Lowe syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16253350     DOI: 10.1016/j.tips.2005.10.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  19 in total

1.  The inositol Inpp5k 5-phosphatase affects osmoregulation through the vasopressin-aquaporin 2 pathway in the collecting system.

Authors:  Eileen Pernot; Sara Terryn; Siew Chiat Cheong; Nicolas Markadieu; Sylvie Janas; Marianne Blockmans; Monique Jacoby; Valérie Pouillon; Stéphanie Gayral; Bernard C Rossier; Renaud Beauwens; Christophe Erneux; Olivier Devuyst; Stéphane Schurmans
Journal:  Pflugers Arch       Date:  2011-09-22       Impact factor: 3.657

2.  Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome.

Authors:  Sergey V Voronov; Samuel G Frere; Silvia Giovedi; Elizabeth A Pollina; Christelle Borel; Hong Zhang; Cecilia Schmidt; Ellen C Akeson; Markus R Wenk; Laurent Cimasoni; Ottavio Arancio; Muriel T Davisson; Stylianos E Antonarakis; Katheleen Gardiner; Pietro De Camilli; Gilbert Di Paolo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-30       Impact factor: 11.205

3.  Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness.

Authors:  Wenting Zhu; Chinmay M Trivedi; Diane Zhou; Lijun Yuan; Min Min Lu; Jonathan A Epstein
Journal:  Circ Res       Date:  2009-10-29       Impact factor: 17.367

Review 4.  Channelopathies linked to plasma membrane phosphoinositides.

Authors:  Diomedes E Logothetis; Vasileios I Petrou; Scott K Adney; Rahul Mahajan
Journal:  Pflugers Arch       Date:  2010-04-16       Impact factor: 3.657

Review 5.  The role of phosphoinositides in synapse function.

Authors:  Yoshibumi Ueda
Journal:  Mol Neurobiol       Date:  2014-06-17       Impact factor: 5.590

6.  Lithium increases synapse formation between hippocampal neurons by depleting phosphoinositides.

Authors:  Hee Jung Kim; Stanley A Thayer
Journal:  Mol Pharmacol       Date:  2009-02-02       Impact factor: 4.436

7.  Distribution and neuronal expression of phosphatidylinositol phosphate kinase IIgamma in the mouse brain.

Authors:  Jonathan H Clarke; Piers C Emson; Robin F Irvine
Journal:  J Comp Neurol       Date:  2009-11-20       Impact factor: 3.215

8.  Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinase/Akt pathway.

Authors:  Ginat Narkis; Rivka Ofir; Esther Manor; Daniella Landau; Khalil Elbedour; Ohad S Birk
Journal:  Am J Hum Genet       Date:  2007-07-24       Impact factor: 11.025

9.  Lethal contractural syndrome type 3 (LCCS3) is caused by a mutation in PIP5K1C, which encodes PIPKI gamma of the phophatidylinsitol pathway.

Authors:  Ginat Narkis; Rivka Ofir; Daniella Landau; Esther Manor; Micha Volokita; Relly Hershkowitz; Khalil Elbedour; Ohad S Birk
Journal:  Am J Hum Genet       Date:  2007-07-24       Impact factor: 11.025

10.  Proteomic studies of a single CNS synapse type: the parallel fiber/purkinje cell synapse.

Authors:  Fekrije Selimi; Ileana M Cristea; Elizabeth Heller; Brian T Chait; Nathaniel Heintz
Journal:  PLoS Biol       Date:  2009-04-14       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.